# OnCo record paper-tracerx-100-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-tracerx-100-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-tracerx-100-nejm-2017" ;
  schema:name "TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse"@en ;
  schema:description "Multi-region sequencing of 327 regions from the first 100 TRACERx lung cancers showed that most driver mutations are early and shared while copy-number chaos continues to evolve, and that tumours with high copy-number heterogeneity were nearly five times more likely to relapse or kill the patient."@en ;
  schema:url <https://onco.cc/key-papers/paper-tracerx-100-nejm-2017/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1616288>, <https://doi.org/10.1038/nature22364>, <https://clinicaltrials.gov/study/NCT01888601>, <https://pubmed.ncbi.nlm.nih.gov/28445112/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1616288> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Jamal-Hanjani M, Wilson GA, McGranahan N, et al. (TRACERx Consortium)" ;
  onco:related <https://onco.cc/key-papers/paper-gerlinger-intratumour-heterogeneity-nejm-2012/>, <https://onco.cc/key-papers/paper-tracerx-evolution-nature-2023/>, <https://onco.cc/terms/whole-genome-doubling/>, <https://onco.cc/ideas/idea-bio1-clonal-neoantigen-vaccines/>, <https://onco.cc/key-papers/paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017/>, <https://onco.cc/key-papers/paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023/>, <https://onco.cc/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/terms/ngs/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/braf/> ;
  onco:institutions <https://onco.cc/institutions/francis-crick/>, <https://onco.cc/institutions/cruk/> ;
  onco:pathways <https://onco.cc/pathways/clonal-evolution/>, <https://onco.cc/pathways/chromosomal-instability/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/biopsy/>, <https://onco.cc/pathways/clonal-evolution/> ;
  onco:people <https://onco.cc/people/charles-swanton/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .